 David Ecker
Concepts (561)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spectrometry, Mass, Electrospray Ionization | 46 | 2019 | 165 | 4.780 |
Why?
| | Polymerase Chain Reaction | 50 | 2020 | 1001 | 3.660 |
Why?
| | Biosensing Techniques | 5 | 2014 | 102 | 1.620 |
Why?
| | Molecular Diagnostic Techniques | 11 | 2016 | 91 | 1.590 |
Why?
| | Bacteria | 13 | 2016 | 730 | 1.180 |
Why?
| | Microbiological Techniques | 6 | 2013 | 29 | 1.110 |
Why?
| | Lyme Disease | 6 | 2020 | 32 | 1.100 |
Why?
| | DNA, Bacterial | 19 | 2016 | 309 | 1.070 |
Why?
| | Ixodes | 5 | 2017 | 10 | 0.920 |
Why?
| | Biohazard Release | 1 | 2023 | 1 | 0.900 |
Why?
| | Communicable Diseases, Emerging | 4 | 2008 | 28 | 0.900 |
Why?
| | Viruses | 6 | 2012 | 94 | 0.900 |
Why?
| | Disease Outbreaks | 5 | 2023 | 308 | 0.890 |
Why?
| | Biological Warfare Agents | 2 | 2013 | 2 | 0.880 |
Why?
| | Genotype | 22 | 2019 | 1830 | 0.800 |
Why?
| | Blood | 5 | 2016 | 97 | 0.790 |
Why?
| | Clinical Competence | 2 | 2018 | 924 | 0.770 |
Why?
| | Sensitivity and Specificity | 19 | 2023 | 1725 | 0.740 |
Why?
| | Bacterial Typing Techniques | 12 | 2013 | 41 | 0.740 |
Why?
| | Borrelia burgdorferi | 5 | 2020 | 12 | 0.720 |
Why?
| | Bacteremia | 6 | 2015 | 159 | 0.720 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 8 | 2013 | 935 | 0.680 |
Why?
| | Drug Design | 5 | 2008 | 156 | 0.670 |
Why?
| | Licensure, Medical | 1 | 2018 | 12 | 0.630 |
Why?
| | Physician Executives | 1 | 2018 | 35 | 0.610 |
Why?
| | Mass Spectrometry | 11 | 2014 | 643 | 0.560 |
Why?
| | Population Surveillance | 3 | 2009 | 395 | 0.550 |
Why?
| | Anaplasmataceae | 1 | 2015 | 1 | 0.530 |
Why?
| | Educational Measurement | 1 | 2018 | 265 | 0.530 |
Why?
| | Base Sequence | 29 | 2012 | 2121 | 0.500 |
Why?
| | Hospitals | 2 | 2023 | 585 | 0.500 |
Why?
| | Virus Diseases | 5 | 2014 | 200 | 0.490 |
Why?
| | DNA Primers | 14 | 2012 | 514 | 0.490 |
Why?
| | DNA, Fungal | 3 | 2014 | 69 | 0.480 |
Why?
| | Candida | 2 | 2013 | 35 | 0.470 |
Why?
| | Bacteriological Techniques | 6 | 2016 | 65 | 0.470 |
Why?
| | Communicable Diseases | 2 | 2013 | 130 | 0.460 |
Why?
| | Civil Defense | 1 | 2013 | 20 | 0.450 |
Why?
| | Acinetobacter baumannii | 6 | 2012 | 15 | 0.440 |
Why?
| | Escherichia coli | 13 | 2015 | 730 | 0.430 |
Why?
| | Biodiversity | 1 | 2015 | 363 | 0.400 |
Why?
| | Point-of-Care Systems | 1 | 2013 | 150 | 0.400 |
Why?
| | Molecular Sequence Data | 25 | 2014 | 2796 | 0.400 |
Why?
| | Oligodeoxyribonucleotides | 5 | 1998 | 138 | 0.390 |
Why?
| | Thionucleotides | 5 | 1998 | 34 | 0.390 |
Why?
| | Respiratory Tract Infections | 4 | 2011 | 323 | 0.390 |
Why?
| | Anti-Bacterial Agents | 7 | 2019 | 1486 | 0.380 |
Why?
| | Borrelia | 5 | 2014 | 5 | 0.380 |
Why?
| | Influenza A virus | 3 | 2011 | 91 | 0.380 |
Why?
| | Acinetobacter Infections | 6 | 2012 | 10 | 0.370 |
Why?
| | Fungemia | 1 | 2010 | 3 | 0.360 |
Why?
| | Molecular Epidemiology | 3 | 2010 | 69 | 0.360 |
Why?
| | Cross Infection | 3 | 2010 | 202 | 0.360 |
Why?
| | Humans | 82 | 2023 | 115859 | 0.350 |
Why?
| | Computer Simulation | 6 | 2023 | 882 | 0.350 |
Why?
| | Rickettsia | 4 | 2017 | 7 | 0.340 |
Why?
| | Acinetobacter | 4 | 2013 | 13 | 0.330 |
Why?
| | Genetics, Microbial | 1 | 2009 | 9 | 0.330 |
Why?
| | Biological Products | 2 | 2009 | 172 | 0.330 |
Why?
| | Staphylococcus aureus | 7 | 2014 | 386 | 0.310 |
Why?
| | Fungi | 6 | 2013 | 122 | 0.310 |
Why?
| | Adenoviridae | 2 | 2011 | 186 | 0.310 |
Why?
| | Drug Discovery | 1 | 2009 | 124 | 0.310 |
Why?
| | Ubiquitins | 9 | 1994 | 34 | 0.300 |
Why?
| | Adenoviridae Infections | 1 | 2007 | 15 | 0.300 |
Why?
| | Oligonucleotides, Antisense | 6 | 1993 | 100 | 0.300 |
Why?
| | Culex | 1 | 2007 | 13 | 0.300 |
Why?
| | Alphavirus | 1 | 2007 | 17 | 0.300 |
Why?
| | Environmental Microbiology | 1 | 2007 | 42 | 0.300 |
Why?
| | RNA, Viral | 7 | 2010 | 564 | 0.300 |
Why?
| | Bacterial Infections | 5 | 2014 | 222 | 0.290 |
Why?
| | Bioterrorism | 3 | 2008 | 19 | 0.290 |
Why?
| | Aedes | 1 | 2007 | 55 | 0.280 |
Why?
| | Microbial Sensitivity Tests | 6 | 2015 | 299 | 0.280 |
Why?
| | Antibody Formation | 1 | 2008 | 274 | 0.280 |
Why?
| | Animals | 35 | 2017 | 32158 | 0.280 |
Why?
| | Base Composition | 6 | 2012 | 76 | 0.270 |
Why?
| | Sequence Alignment | 3 | 2010 | 328 | 0.270 |
Why?
| | HIV-1 | 5 | 1998 | 771 | 0.260 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2023 | 446 | 0.260 |
Why?
| | Klebsiella pneumoniae | 3 | 2015 | 41 | 0.260 |
Why?
| | RNA | 10 | 2010 | 820 | 0.260 |
Why?
| | 5' Untranslated Regions | 2 | 2004 | 51 | 0.250 |
Why?
| | Coronaviridae Infections | 1 | 2005 | 3 | 0.250 |
Why?
| | Coronaviridae | 1 | 2005 | 3 | 0.250 |
Why?
| | DNA, Viral | 6 | 2014 | 351 | 0.250 |
Why?
| | Nucleic Acid Conformation | 11 | 2005 | 672 | 0.250 |
Why?
| | Sentinel Surveillance | 1 | 2005 | 38 | 0.250 |
Why?
| | Databases, Factual | 3 | 2008 | 1137 | 0.250 |
Why?
| | Antiviral Agents | 4 | 1994 | 651 | 0.240 |
Why?
| | Chromosome Mapping | 2 | 2004 | 505 | 0.240 |
Why?
| | Tick-Borne Diseases | 3 | 2020 | 3 | 0.240 |
Why?
| | Candidemia | 2 | 2014 | 6 | 0.230 |
Why?
| | Oligonucleotides | 4 | 1997 | 138 | 0.230 |
Why?
| | Drug Resistance, Bacterial | 5 | 2013 | 156 | 0.230 |
Why?
| | Virulence Factors | 1 | 2005 | 139 | 0.230 |
Why?
| | beta-Lactam Resistance | 2 | 2015 | 6 | 0.220 |
Why?
| | Symbiosis | 2 | 2015 | 65 | 0.220 |
Why?
| | Pharmacology | 1 | 2003 | 8 | 0.220 |
Why?
| | Mycoses | 4 | 2014 | 67 | 0.220 |
Why?
| | Saccharomyces cerevisiae | 10 | 1994 | 482 | 0.220 |
Why?
| | Embryonic Development | 1 | 2004 | 115 | 0.220 |
Why?
| | Genes, Bacterial | 5 | 2013 | 156 | 0.210 |
Why?
| | Staphylococcal Infections | 3 | 2014 | 338 | 0.210 |
Why?
| | Virology | 2 | 2013 | 19 | 0.210 |
Why?
| | Schools, Medical | 1 | 2023 | 125 | 0.210 |
Why?
| | Sequence Analysis, RNA | 1 | 2004 | 390 | 0.210 |
Why?
| | Faculty | 1 | 2023 | 131 | 0.210 |
Why?
| | Oligoribonucleotides | 2 | 1992 | 52 | 0.200 |
Why?
| | Central Nervous System Infections | 2 | 2012 | 36 | 0.190 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 1891 | 0.190 |
Why?
| | Borrelia burgdorferi Group | 1 | 2020 | 8 | 0.190 |
Why?
| | Gene Expression Regulation | 7 | 2004 | 2365 | 0.190 |
Why?
| | Anaplasma phagocytophilum | 2 | 2017 | 2 | 0.180 |
Why?
| | Babesia | 2 | 2017 | 3 | 0.180 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2011 | 46 | 0.180 |
Why?
| | Behavior, Animal | 1 | 2004 | 472 | 0.180 |
Why?
| | HIV | 2 | 1992 | 209 | 0.180 |
Why?
| | California | 2 | 2015 | 368 | 0.170 |
Why?
| | Benzoates | 1 | 1999 | 38 | 0.170 |
Why?
| | Genetic Techniques | 2 | 2005 | 57 | 0.170 |
Why?
| | Streptococcus pneumoniae | 2 | 2012 | 133 | 0.170 |
Why?
| | Sepsis | 2 | 2016 | 521 | 0.160 |
Why?
| | Metallothionein | 8 | 1994 | 24 | 0.160 |
Why?
| | Ribosomes | 3 | 2005 | 148 | 0.160 |
Why?
| | Streptococcal Infections | 2 | 2012 | 132 | 0.160 |
Why?
| | Sequence Analysis, DNA | 4 | 2015 | 737 | 0.160 |
Why?
| | Quinazolines | 1 | 1999 | 241 | 0.150 |
Why?
| | Tick Infestations | 1 | 2017 | 4 | 0.150 |
Why?
| | Cell Fusion | 2 | 1994 | 50 | 0.150 |
Why?
| | Evolution, Molecular | 3 | 2012 | 442 | 0.150 |
Why?
| | HIV Envelope Protein gp120 | 2 | 1994 | 56 | 0.140 |
Why?
| | Communicable Disease Control | 2 | 2008 | 66 | 0.140 |
Why?
| | Pneumonia, Bacterial | 2 | 2015 | 108 | 0.140 |
Why?
| | Specimen Handling | 2 | 2015 | 157 | 0.140 |
Why?
| | Glossitis, Benign Migratory | 2 | 2013 | 5 | 0.140 |
Why?
| | Ticks | 3 | 2012 | 12 | 0.140 |
Why?
| | Structure-Activity Relationship | 5 | 1999 | 511 | 0.140 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2012 | 2004 | 0.140 |
Why?
| | Phylogeny | 3 | 2015 | 806 | 0.130 |
Why?
| | Klebsiella Infections | 2 | 2010 | 23 | 0.130 |
Why?
| | Drug Evaluation, Preclinical | 4 | 1997 | 165 | 0.130 |
Why?
| | Blood-Borne Pathogens | 1 | 2015 | 6 | 0.130 |
Why?
| | Nucleosides | 1 | 1995 | 25 | 0.130 |
Why?
| | Models, Biological | 1 | 2003 | 1647 | 0.130 |
Why?
| | Chemistry, Pharmaceutical | 2 | 1995 | 99 | 0.130 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 33 | 0.130 |
Why?
| | Cluster Analysis | 3 | 2012 | 466 | 0.130 |
Why?
| | Neoplasms | 1 | 2009 | 2114 | 0.130 |
Why?
| | Models, Chemical | 2 | 1996 | 257 | 0.120 |
Why?
| | Streptococcus pyogenes | 2 | 2009 | 33 | 0.120 |
Why?
| | HIV-2 | 1 | 1994 | 15 | 0.120 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2015 | 88 | 0.120 |
Why?
| | Simplexvirus | 2 | 1993 | 83 | 0.120 |
Why?
| | Babesia microti | 1 | 2014 | 1 | 0.120 |
Why?
| | Species Specificity | 4 | 2012 | 553 | 0.120 |
Why?
| | Health Care Reform | 1 | 2015 | 92 | 0.120 |
Why?
| | Carbapenems | 2 | 2013 | 16 | 0.120 |
Why?
| | Genes, Fungal | 4 | 1994 | 49 | 0.120 |
Why?
| | Conserved Sequence | 2 | 2005 | 220 | 0.120 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 1842 | 0.120 |
Why?
| | Bacterial Proteins | 5 | 2011 | 740 | 0.120 |
Why?
| | Hand, Foot and Mouth Disease | 1 | 2013 | 3 | 0.120 |
Why?
| | Statistics as Topic | 2 | 2012 | 299 | 0.120 |
Why?
| | Venous Thrombosis | 1 | 2015 | 147 | 0.110 |
Why?
| | Serologic Tests | 1 | 2013 | 51 | 0.110 |
Why?
| | Europe | 4 | 2016 | 343 | 0.110 |
Why?
| | Multilocus Sequence Typing | 1 | 2013 | 12 | 0.110 |
Why?
| | Mastitis, Bovine | 1 | 2013 | 2 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 182 | 0.110 |
Why?
| | Aza Compounds | 1 | 2013 | 11 | 0.110 |
Why?
| | Povidone-Iodine | 1 | 2013 | 11 | 0.110 |
Why?
| | Mycology | 1 | 2013 | 3 | 0.110 |
Why?
| | Enterovirus | 1 | 2013 | 72 | 0.110 |
Why?
| | Streptococcus intermedius | 1 | 2012 | 1 | 0.110 |
Why?
| | Eye Infections, Bacterial | 1 | 2013 | 26 | 0.110 |
Why?
| | Genes | 3 | 1989 | 224 | 0.110 |
Why?
| | Francisella tularensis | 1 | 2012 | 19 | 0.110 |
Why?
| | Infection Control | 1 | 2014 | 137 | 0.110 |
Why?
| | Fusion Proteins, gag-pol | 1 | 1992 | 2 | 0.110 |
Why?
| | DNA | 7 | 2010 | 1357 | 0.110 |
Why?
| | RNA, Bacterial | 5 | 2013 | 173 | 0.110 |
Why?
| | Frameshift Mutation | 1 | 1992 | 27 | 0.110 |
Why?
| | Dirofilariasis | 1 | 2012 | 1 | 0.110 |
Why?
| | Ixodidae | 1 | 2012 | 5 | 0.110 |
Why?
| | Antitubercular Agents | 2 | 2011 | 170 | 0.100 |
Why?
| | False Negative Reactions | 1 | 2012 | 52 | 0.100 |
Why?
| | Limit of Detection | 1 | 2012 | 55 | 0.100 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2013 | 61 | 0.100 |
Why?
| | Diarrhea | 1 | 2013 | 173 | 0.100 |
Why?
| | Milk | 1 | 2013 | 124 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 1995 | 758 | 0.100 |
Why?
| | Quinolines | 1 | 2013 | 129 | 0.100 |
Why?
| | Dog Diseases | 1 | 2012 | 41 | 0.100 |
Why?
| | RNA, Antisense | 1 | 1991 | 16 | 0.100 |
Why?
| | Biological Assay | 1 | 2012 | 114 | 0.100 |
Why?
| | Signal Transduction | 1 | 2004 | 4527 | 0.100 |
Why?
| | Research Report | 1 | 2012 | 76 | 0.100 |
Why?
| | RNA Caps | 1 | 1991 | 31 | 0.100 |
Why?
| | Male | 19 | 2016 | 56103 | 0.100 |
Why?
| | Prostheses and Implants | 1 | 2013 | 141 | 0.100 |
Why?
| | HIV Long Terminal Repeat | 1 | 1991 | 7 | 0.100 |
Why?
| | Serotyping | 2 | 2008 | 28 | 0.100 |
Why?
| | Xenotropic murine leukemia virus-related virus | 1 | 2011 | 1 | 0.100 |
Why?
| | Nucleic Acids | 1 | 2012 | 59 | 0.100 |
Why?
| | Molecular Typing | 1 | 2011 | 17 | 0.100 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2011 | 16 | 0.100 |
Why?
| | Middle Aged | 13 | 2016 | 27078 | 0.100 |
Why?
| | Hospitals, Military | 2 | 2008 | 33 | 0.090 |
Why?
| | Feces | 1 | 2013 | 373 | 0.090 |
Why?
| | Female | 19 | 2016 | 60070 | 0.090 |
Why?
| | Mutation | 5 | 1996 | 3371 | 0.090 |
Why?
| | Mycoplasma | 1 | 2010 | 4 | 0.090 |
Why?
| | Nasopharynx | 1 | 2011 | 63 | 0.090 |
Why?
| | Medicare | 1 | 2015 | 666 | 0.090 |
Why?
| | Pyoderma Gangrenosum | 1 | 2010 | 5 | 0.090 |
Why?
| | Disease Vectors | 1 | 2010 | 11 | 0.090 |
Why?
| | Helicobacter | 1 | 2010 | 5 | 0.090 |
Why?
| | Adult | 15 | 2016 | 30814 | 0.090 |
Why?
| | Young Adult | 7 | 2016 | 10508 | 0.090 |
Why?
| | Military Personnel | 3 | 2006 | 526 | 0.090 |
Why?
| | beta-Lactamases | 1 | 2010 | 26 | 0.090 |
Why?
| | Enterobacteriaceae | 1 | 2010 | 33 | 0.090 |
Why?
| | Flavivirus | 1 | 2010 | 16 | 0.090 |
Why?
| | Helicobacter Infections | 1 | 2010 | 26 | 0.090 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2010 | 35 | 0.090 |
Why?
| | Ehrlichia | 1 | 2009 | 1 | 0.090 |
Why?
| | Agammaglobulinemia | 1 | 2010 | 31 | 0.090 |
Why?
| | Ehrlichiosis | 1 | 2009 | 3 | 0.090 |
Why?
| | Time Factors | 5 | 2015 | 6182 | 0.090 |
Why?
| | Orthopoxvirus | 1 | 2009 | 1 | 0.090 |
Why?
| | Aged | 9 | 2016 | 19292 | 0.080 |
Why?
| | Protozoan Infections | 2 | 2008 | 10 | 0.080 |
Why?
| | United States | 6 | 2018 | 12319 | 0.080 |
Why?
| | Mycobacterium | 1 | 2010 | 103 | 0.080 |
Why?
| | Transcription, Genetic | 4 | 1999 | 1317 | 0.080 |
Why?
| | Metals | 2 | 1986 | 110 | 0.080 |
Why?
| | Nucleic Acid Hybridization | 6 | 1996 | 189 | 0.080 |
Why?
| | Peptide Library | 3 | 1999 | 81 | 0.080 |
Why?
| | Yeasts | 2 | 2013 | 51 | 0.080 |
Why?
| | Adolescent | 11 | 2016 | 17935 | 0.080 |
Why?
| | Monte Carlo Method | 4 | 1997 | 140 | 0.080 |
Why?
| | Eukaryota | 2 | 2008 | 47 | 0.080 |
Why?
| | Disulfides | 1 | 1989 | 91 | 0.080 |
Why?
| | Thalassemia | 1 | 2008 | 7 | 0.080 |
Why?
| | Marine Toxins | 1 | 2008 | 12 | 0.080 |
Why?
| | Porifera | 1 | 2008 | 8 | 0.080 |
Why?
| | Campylobacter | 1 | 2008 | 5 | 0.080 |
Why?
| | Chlamydiales | 1 | 2007 | 1 | 0.080 |
Why?
| | Infant | 5 | 2013 | 7992 | 0.080 |
Why?
| | Mycobacterium tuberculosis | 1 | 2011 | 271 | 0.080 |
Why?
| | Receptor, IGF Type 1 | 1 | 2008 | 58 | 0.080 |
Why?
| | Pneumococcal Infections | 1 | 2008 | 91 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 97 | 0.070 |
Why?
| | Child, Preschool | 5 | 2013 | 9164 | 0.070 |
Why?
| | Warfare | 1 | 2008 | 75 | 0.070 |
Why?
| | Prevalence | 4 | 2014 | 2270 | 0.070 |
Why?
| | Cancer Vaccines | 1 | 2008 | 137 | 0.070 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2013 | 489 | 0.070 |
Why?
| | Adenovirus Infections, Human | 1 | 2006 | 12 | 0.070 |
Why?
| | Adenoviruses, Human | 1 | 2006 | 24 | 0.070 |
Why?
| | Aged, 80 and over | 6 | 2016 | 6434 | 0.070 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2006 | 62 | 0.070 |
Why?
| | Plasmids | 5 | 1992 | 346 | 0.070 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2008 | 193 | 0.070 |
Why?
| | Prospective Studies | 5 | 2016 | 6276 | 0.070 |
Why?
| | RNA Interference | 1 | 2008 | 438 | 0.070 |
Why?
| | Mice | 8 | 2017 | 15085 | 0.070 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2005 | 13 | 0.070 |
Why?
| | Pharmaceutical Preparations | 1 | 2008 | 169 | 0.070 |
Why?
| | Forensic Sciences | 1 | 2005 | 6 | 0.070 |
Why?
| | Phospholipases A | 2 | 1996 | 101 | 0.070 |
Why?
| | DNA Fingerprinting | 3 | 2010 | 27 | 0.060 |
Why?
| | Binding Sites | 4 | 2005 | 1182 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 5 | 1992 | 617 | 0.060 |
Why?
| | Virus Replication | 4 | 2005 | 396 | 0.060 |
Why?
| | Genetic Variation | 1 | 2010 | 893 | 0.060 |
Why?
| | Early Diagnosis | 2 | 2016 | 220 | 0.060 |
Why?
| | Bacillus anthracis | 1 | 2004 | 11 | 0.060 |
Why?
| | Benzimidazoles | 1 | 2005 | 137 | 0.060 |
Why?
| | Genotyping Techniques | 2 | 2015 | 72 | 0.060 |
Why?
| | Genetic Engineering | 1 | 2005 | 81 | 0.060 |
Why?
| | Protein Precursors | 2 | 1999 | 119 | 0.060 |
Why?
| | DNA, Mitochondrial | 1 | 2005 | 186 | 0.060 |
Why?
| | Kinetics | 9 | 1999 | 1568 | 0.060 |
Why?
| | Maze Learning | 1 | 2004 | 87 | 0.060 |
Why?
| | Hepacivirus | 1 | 2005 | 234 | 0.060 |
Why?
| | Videotape Recording | 1 | 2023 | 30 | 0.060 |
Why?
| | Child | 6 | 2013 | 18537 | 0.060 |
Why?
| | Chemistry | 1 | 2003 | 39 | 0.060 |
Why?
| | Amino Acid Sequence | 5 | 1992 | 2003 | 0.050 |
Why?
| | Genomics | 1 | 2008 | 653 | 0.050 |
Why?
| | Chemical Phenomena | 1 | 2003 | 81 | 0.050 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 576 | 0.050 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2002 | 18 | 0.050 |
Why?
| | Algorithms | 3 | 2011 | 1494 | 0.050 |
Why?
| | Writing | 1 | 2023 | 85 | 0.050 |
Why?
| | Animals, Genetically Modified | 1 | 2003 | 216 | 0.050 |
Why?
| | Gene Products, tat | 2 | 1992 | 19 | 0.050 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 1992 | 20 | 0.050 |
Why?
| | Antibodies, Bacterial | 2 | 2013 | 119 | 0.050 |
Why?
| | Thermodynamics | 5 | 1995 | 388 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 413 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1264 | 0.050 |
Why?
| | Cerebrospinal Fluid | 2 | 2012 | 88 | 0.050 |
Why?
| | Minisatellite Repeats | 2 | 2012 | 39 | 0.050 |
Why?
| | Cell Line | 3 | 2005 | 2657 | 0.050 |
Why?
| | Ohio | 2 | 2012 | 136 | 0.050 |
Why?
| | Critical Illness | 2 | 2016 | 648 | 0.050 |
Why?
| | Reproducibility of Results | 3 | 2013 | 2807 | 0.050 |
Why?
| | Models, Molecular | 1 | 2005 | 1391 | 0.050 |
Why?
| | Encephalitis Viruses, Tick-Borne | 2 | 2010 | 7 | 0.040 |
Why?
| | Point Mutation | 2 | 2009 | 218 | 0.040 |
Why?
| | Enterococcus faecalis | 1 | 1999 | 23 | 0.040 |
Why?
| | RNA, Ribosomal, 18S | 1 | 1999 | 22 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 1999 | 111 | 0.040 |
Why?
| | Splanchnic Circulation | 1 | 1999 | 11 | 0.040 |
Why?
| | Extracorporeal Circulation | 1 | 1999 | 14 | 0.040 |
Why?
| | Protein Biosynthesis | 2 | 1999 | 390 | 0.040 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 2 | 2009 | 17 | 0.040 |
Why?
| | Calcitonin | 1 | 1999 | 23 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1999 | 125 | 0.040 |
Why?
| | Computational Biology | 1 | 2002 | 540 | 0.040 |
Why?
| | RNA, Messenger | 5 | 1994 | 2581 | 0.040 |
Why?
| | Mutation, Missense | 2 | 2011 | 296 | 0.040 |
Why?
| | Genetic Markers | 2 | 2012 | 336 | 0.040 |
Why?
| | Artiodactyla | 1 | 2017 | 2 | 0.040 |
Why?
| | Czech Republic | 1 | 2017 | 3 | 0.040 |
Why?
| | Recombinant Proteins | 3 | 1994 | 1244 | 0.040 |
Why?
| | Sus scrofa | 1 | 2017 | 45 | 0.040 |
Why?
| | Deer | 1 | 2017 | 24 | 0.040 |
Why?
| | Arvicolinae | 1 | 2017 | 24 | 0.040 |
Why?
| | Anxiety | 1 | 2004 | 854 | 0.040 |
Why?
| | Birds | 1 | 2017 | 77 | 0.040 |
Why?
| | Auranofin | 2 | 1987 | 9 | 0.040 |
Why?
| | Risk Assessment | 2 | 2016 | 2992 | 0.040 |
Why?
| | GTP-Binding Proteins | 2 | 1994 | 142 | 0.030 |
Why?
| | HeLa Cells | 3 | 1993 | 567 | 0.030 |
Why?
| | Sciuridae | 1 | 2017 | 142 | 0.030 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 1996 | 82 | 0.030 |
Why?
| | Endopeptidases | 3 | 1994 | 72 | 0.030 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1995 | 8 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 1995 | 48 | 0.030 |
Why?
| | Body Fluids | 1 | 2015 | 58 | 0.030 |
Why?
| | Gram-Positive Bacteria | 1 | 2015 | 46 | 0.030 |
Why?
| | Binding, Competitive | 1 | 1995 | 200 | 0.030 |
Why?
| | Gram-Negative Bacteria | 1 | 2015 | 67 | 0.030 |
Why?
| | Esters | 1 | 1995 | 61 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 1993 | 228 | 0.030 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 1994 | 16 | 0.030 |
Why?
| | Biotechnology | 1 | 1995 | 46 | 0.030 |
Why?
| | Arthropod Vectors | 1 | 2014 | 7 | 0.030 |
Why?
| | Macromolecular Substances | 1 | 1995 | 200 | 0.030 |
Why?
| | Adenylyl Cyclases | 1 | 1994 | 84 | 0.030 |
Why?
| | Automation, Laboratory | 1 | 2014 | 7 | 0.030 |
Why?
| | Zidovudine | 1 | 1994 | 77 | 0.030 |
Why?
| | Germany | 1 | 2014 | 88 | 0.030 |
Why?
| | Mupirocin | 1 | 2014 | 7 | 0.030 |
Why?
| | Maryland | 1 | 2014 | 37 | 0.030 |
Why?
| | Methicillin Resistance | 1 | 2014 | 18 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 1998 | 1871 | 0.030 |
Why?
| | Fungal Proteins | 1 | 1994 | 124 | 0.030 |
Why?
| | Tritium | 1 | 1993 | 69 | 0.030 |
Why?
| | Amplified Fragment Length Polymorphism Analysis | 1 | 2013 | 1 | 0.030 |
Why?
| | Nose | 1 | 2014 | 56 | 0.030 |
Why?
| | Bangladesh | 1 | 2013 | 30 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1218 | 0.030 |
Why?
| | Arizona | 1 | 2013 | 67 | 0.030 |
Why?
| | Africa | 1 | 2013 | 99 | 0.030 |
Why?
| | Fluoroquinolones | 1 | 2013 | 41 | 0.030 |
Why?
| | Corneal Diseases | 1 | 2013 | 34 | 0.030 |
Why?
| | Iron | 2 | 2002 | 235 | 0.030 |
Why?
| | Virulence | 1 | 1994 | 231 | 0.030 |
Why?
| | Endophthalmitis | 1 | 2013 | 25 | 0.030 |
Why?
| | Gene Library | 1 | 1993 | 117 | 0.030 |
Why?
| | Tularemia | 1 | 2012 | 16 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2013 | 40 | 0.030 |
Why?
| | Brain Abscess | 1 | 2012 | 11 | 0.030 |
Why?
| | Nymph | 1 | 2012 | 4 | 0.030 |
Why?
| | Cattle | 2 | 2013 | 935 | 0.030 |
Why?
| | Prosthesis-Related Infections | 1 | 2013 | 70 | 0.030 |
Why?
| | Reticulocytes | 2 | 1989 | 17 | 0.030 |
Why?
| | Ovum | 1 | 2012 | 28 | 0.030 |
Why?
| | Genes, ras | 1 | 1992 | 91 | 0.030 |
Why?
| | Rabbits | 2 | 2009 | 754 | 0.030 |
Why?
| | Cloning, Molecular | 3 | 1989 | 523 | 0.030 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2010 | 58 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2012 | 80 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 96 | 0.030 |
Why?
| | Anti-HIV Agents | 1 | 1998 | 669 | 0.030 |
Why?
| | Pregnancy | 1 | 2004 | 5555 | 0.030 |
Why?
| | Ribonuclease H | 1 | 1991 | 11 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1992 | 80 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 1989 | 484 | 0.030 |
Why?
| | Nucleic Acid Denaturation | 1 | 1991 | 31 | 0.030 |
Why?
| | Microbial Viability | 1 | 2012 | 79 | 0.020 |
Why?
| | Adenosine | 1 | 1993 | 204 | 0.020 |
Why?
| | Ligases | 2 | 1989 | 32 | 0.020 |
Why?
| | Genome, Bacterial | 1 | 2012 | 106 | 0.020 |
Why?
| | Cell Cycle | 1 | 1994 | 546 | 0.020 |
Why?
| | Larva | 1 | 2012 | 193 | 0.020 |
Why?
| | Critical Care | 1 | 2015 | 480 | 0.020 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 193 | 0.020 |
Why?
| | Parainfluenza Virus 2, Human | 1 | 2011 | 3 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2015 | 624 | 0.020 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2011 | 5 | 0.020 |
Why?
| | Liver | 1 | 1999 | 1693 | 0.020 |
Why?
| | Endemic Diseases | 1 | 2011 | 28 | 0.020 |
Why?
| | Georgia (Republic) | 1 | 2010 | 2 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 344 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 313 | 0.020 |
Why?
| | Phenotype | 2 | 2009 | 2859 | 0.020 |
Why?
| | Influenza B virus | 1 | 2011 | 34 | 0.020 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2011 | 47 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2011 | 42 | 0.020 |
Why?
| | New York City | 1 | 2010 | 74 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 1991 | 144 | 0.020 |
Why?
| | China | 1 | 2011 | 165 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 204 | 0.020 |
Why?
| | Isoniazid | 1 | 2010 | 52 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1994 | 675 | 0.020 |
Why?
| | Rifampin | 1 | 2010 | 68 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2013 | 5084 | 0.020 |
Why?
| | South Africa | 1 | 2010 | 162 | 0.020 |
Why?
| | Flavivirus Infections | 1 | 2010 | 9 | 0.020 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2010 | 23 | 0.020 |
Why?
| | Culicidae | 1 | 2010 | 29 | 0.020 |
Why?
| | Water | 1 | 1993 | 413 | 0.020 |
Why?
| | Rickettsia rickettsii | 1 | 2009 | 1 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 962 | 0.020 |
Why?
| | DNA, Protozoan | 1 | 2010 | 26 | 0.020 |
Why?
| | Dengue Virus | 1 | 2010 | 31 | 0.020 |
Why?
| | Neisseria meningitidis | 1 | 2009 | 19 | 0.020 |
Why?
| | West Nile virus | 1 | 2010 | 38 | 0.020 |
Why?
| | RNA, Protozoan | 1 | 2010 | 57 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 2010 | 112 | 0.020 |
Why?
| | Geography | 1 | 2010 | 183 | 0.020 |
Why?
| | DNA Topoisomerase IV | 1 | 2009 | 1 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2009 | 150 | 0.020 |
Why?
| | North America | 1 | 2010 | 263 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 1991 | 341 | 0.020 |
Why?
| | Genetic Vectors | 2 | 1988 | 298 | 0.020 |
Why?
| | DNA Gyrase | 1 | 2009 | 12 | 0.020 |
Why?
| | Cystine | 1 | 1989 | 14 | 0.020 |
Why?
| | Protein Binding | 1 | 1994 | 1918 | 0.020 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1989 | 78 | 0.020 |
Why?
| | Bacterial Toxins | 1 | 2009 | 103 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1359 | 0.020 |
Why?
| | Temperature | 1 | 1991 | 588 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 3344 | 0.020 |
Why?
| | Molecular Weight | 4 | 1990 | 331 | 0.020 |
Why?
| | Genetic Loci | 1 | 2010 | 280 | 0.020 |
Why?
| | Cells, Cultured | 2 | 1994 | 3914 | 0.020 |
Why?
| | Forensic Medicine | 1 | 2008 | 16 | 0.020 |
Why?
| | Government Agencies | 1 | 2008 | 15 | 0.020 |
Why?
| | Multigene Family | 1 | 1989 | 198 | 0.020 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1989 | 133 | 0.020 |
Why?
| | Campylobacter coli | 1 | 2008 | 1 | 0.020 |
Why?
| | Viral Load | 1 | 2010 | 406 | 0.020 |
Why?
| | Campylobacter jejuni | 1 | 2008 | 11 | 0.020 |
Why?
| | Acute Disease | 1 | 2011 | 917 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1994 | 967 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 1994 | 1130 | 0.020 |
Why?
| | User-Computer Interface | 1 | 2008 | 146 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 2009 | 303 | 0.020 |
Why?
| | Gene Expression | 1 | 1992 | 1442 | 0.020 |
Why?
| | Phosphines | 1 | 1986 | 15 | 0.020 |
Why?
| | Enterobactin | 1 | 1986 | 6 | 0.020 |
Why?
| | Sequence Homology | 1 | 2006 | 40 | 0.020 |
Why?
| | Decision Making | 1 | 2013 | 790 | 0.020 |
Why?
| | Oligopeptides | 1 | 1988 | 248 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4673 | 0.020 |
Why?
| | Protein Conformation | 1 | 1989 | 822 | 0.020 |
Why?
| | Serine | 1 | 1986 | 125 | 0.020 |
Why?
| | DNA Restriction Enzymes | 1 | 2005 | 54 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 33 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 1986 | 102 | 0.020 |
Why?
| | Housing | 1 | 2006 | 115 | 0.020 |
Why?
| | Automation | 1 | 2005 | 73 | 0.020 |
Why?
| | Molecular Structure | 2 | 1996 | 447 | 0.020 |
Why?
| | Ovary | 1 | 1986 | 190 | 0.020 |
Why?
| | Tandem Repeat Sequences | 1 | 2004 | 17 | 0.020 |
Why?
| | Fourier Analysis | 1 | 2004 | 40 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1813 | 0.020 |
Why?
| | Fibroblasts | 1 | 1989 | 838 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 1986 | 358 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 4443 | 0.010 |
Why?
| | Signal Recognition Particle | 1 | 2002 | 8 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2006 | 527 | 0.010 |
Why?
| | Genetic Complementation Test | 2 | 1994 | 61 | 0.010 |
Why?
| | Ferritins | 1 | 2002 | 57 | 0.010 |
Why?
| | RNA, Ribosomal, 23S | 1 | 2001 | 12 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 817 | 0.010 |
Why?
| | Copper | 2 | 1994 | 101 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2001 | 137 | 0.010 |
Why?
| | Pilot Projects | 1 | 2005 | 1379 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 8715 | 0.010 |
Why?
| | Aminoglycosides | 1 | 1999 | 13 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 2749 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 2 | 1994 | 401 | 0.010 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 1999 | 32 | 0.010 |
Why?
| | Ubiquitin-Activating Enzymes | 2 | 1989 | 13 | 0.010 |
Why?
| | RNA, Ribosomal | 1 | 1999 | 157 | 0.010 |
Why?
| | Postoperative Period | 1 | 1999 | 292 | 0.010 |
Why?
| | Coronary Artery Bypass | 1 | 1999 | 196 | 0.010 |
Why?
| | Mice, SCID | 1 | 1998 | 321 | 0.010 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 1989 | 141 | 0.010 |
Why?
| | Ligands | 1 | 1999 | 570 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 221 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 1996 | 76 | 0.010 |
Why?
| | Cadmium | 2 | 1987 | 58 | 0.010 |
Why?
| | Cricetinae | 2 | 1987 | 260 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 170 | 0.010 |
Why?
| | Gold | 2 | 1986 | 107 | 0.010 |
Why?
| | Transducin | 1 | 1994 | 40 | 0.010 |
Why?
| | RNA, Fungal | 1 | 1994 | 65 | 0.010 |
Why?
| | Genes, Dominant | 1 | 1994 | 93 | 0.010 |
Why?
| | Mercaptoethanol | 1 | 1993 | 11 | 0.010 |
Why?
| | Methods | 1 | 1993 | 59 | 0.010 |
Why?
| | Cell Survival | 2 | 1987 | 1024 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1993 | 135 | 0.010 |
Why?
| | Bovine papillomavirus 1 | 1 | 1992 | 1 | 0.010 |
Why?
| | Lysine | 1 | 1994 | 246 | 0.010 |
Why?
| | Luciferases | 1 | 1992 | 141 | 0.010 |
Why?
| | Codon | 1 | 1992 | 86 | 0.010 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1992 | 155 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1993 | 850 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 1992 | 169 | 0.010 |
Why?
| | Cytokines | 1 | 1999 | 1858 | 0.010 |
Why?
| | Cell Membrane | 1 | 1994 | 683 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1998 | 1758 | 0.010 |
Why?
| | Chromosome Deletion | 1 | 1990 | 95 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2006 | 12615 | 0.010 |
Why?
| | Butyric Acid | 1 | 1989 | 5 | 0.010 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 1989 | 9 | 0.010 |
Why?
| | Chromatography, Ion Exchange | 1 | 1989 | 48 | 0.010 |
Why?
| | Electrophoresis | 1 | 1989 | 25 | 0.010 |
Why?
| | Copper Sulfate | 1 | 1988 | 6 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1998 | 3587 | 0.010 |
Why?
| | Butyrates | 1 | 1989 | 53 | 0.010 |
Why?
| | Methylation | 1 | 1989 | 206 | 0.010 |
Why?
| | Membrane Proteins | 1 | 1994 | 1033 | 0.000 |
Why?
| | Substrate Specificity | 1 | 1989 | 357 | 0.000 |
Why?
| | Hydrolysis | 1 | 1988 | 179 | 0.000 |
Why?
| | Dexamethasone | 1 | 1989 | 315 | 0.000 |
Why?
| | Organogold Compounds | 1 | 1986 | 5 | 0.000 |
Why?
| | Cell Compartmentation | 1 | 1986 | 52 | 0.000 |
Why?
| | Cricetulus | 1 | 1986 | 99 | 0.000 |
Why?
| | Drug Resistance | 1 | 1987 | 162 | 0.000 |
Why?
| | Osmolar Concentration | 1 | 1986 | 178 | 0.000 |
Why?
| | Albumins | 1 | 1986 | 91 | 0.000 |
Why?
| | Spectrum Analysis | 1 | 1986 | 81 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1986 | 324 | 0.000 |
Why?
| | Adenosine Triphosphate | 1 | 1988 | 430 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1986 | 515 | 0.000 |
Why?
| | Sulfhydryl Compounds | 1 | 1986 | 178 | 0.000 |
Why?
| | Amino Acids | 1 | 1987 | 456 | 0.000 |
Why?
| | Polymers | 1 | 1987 | 464 | 0.000 |
Why?
| | Zinc | 1 | 1986 | 257 | 0.000 |
Why?
| | Carrier Proteins | 1 | 1986 | 703 | 0.000 |
Why?
| | Proteins | 1 | 1986 | 920 | 0.000 |
Why?
|
|
Ecker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|